Travere Therapeutics Stock Story
| TVTX Stock | USD 5.45 0.29 5.05% |
Slightly above 59% of Travere Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that many traders are alarmed. Travere Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Travere Therapeutics. The current market sentiment, together with Travere Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Travere Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Travere Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Travere daily returns and investor perception about the current price of Travere Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Travere |
Requested story not found. it has been either deleted or moved. View all stories for Travere Therapeutics.
Travere Therapeutics Latest Timeline
Travere Therapeutics is listed for 5.45. About 99.0% of the company shares are owned by institutional investors. The book value of Travere Therapeutics was at this time reported as 2.66. The company recorded a loss per share of 5.07. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011.Check out Travere Therapeutics Hype Analysis, Travere Therapeutics Correlation and Travere Therapeutics Performance. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Travere Stock analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Travere Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.07) | Revenue Per Share 1.956 | Quarterly Revenue Growth 0.536 | Return On Assets (0.32) | Return On Equity (3.09) |
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.